Mucormycosis, Epidemiology


Last updated: 2021 Sep 28
Total hit(s): 2
Select item(s)
Key Findings
Comments
(You can add your comments too!)
Original Article
(hover to see details)
In the September-December 2019 study period, there was a 2.1-fold increase in mucormycosis. The most frequent underlying condition among COVID-19 associated mucormycosis (CAM) and non-CAM patients was uncontrolled diabetes mellitus. In 32.6% of CAM patients, COVID-19 was the only underlying illness. COVID-19-related hypoxemia and incorrect glucocorticoid use were both linked to CAM. Majority of the patients with CAM had hypoxia and required ICU admission. The most common mucormycosis location was the rhino-orbital area (58.2%), followed by rhino-orbital-cerebral, pulmonary, and other sites.
34087089
(Emerg Infect Dis)
PMID
34087089
Date of Publishing: 2021 Jun 4
Title Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India
Author(s) namePatel A, Agarwal R et al.
Journal Emerg Infect Dis
Impact factor
6.81
Citation count: 2
Date of Entry 2021 Sep 28


At 12 weeks, the case-fatality rate for mucormycosis was 45.7 percent, with no difference between COVID-19-associated mucormycosis (CAM) and non-CAM patients. Age, involvement of the rhino-orbital-cerebral system, and admission to an intensive care unit were all linked to higher fatality rates; however, periodic antifungal treatment improved mucormycosis survival. In both groups, liposomal amphotericin B was the most commonly utilised antifungal agent. When compared to the non-CAM group, the utilisation of liposomal amphotericin B was substantially lower in the CAM group (72.7% Vs 84%). Combined medical and surgical management was similar between both the groups.
34087089
(Emerg Infect Dis)
PMID
34087089
Date of Publishing: 2021 Jun 4
Title Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India
Author(s) namePatel A, Agarwal R et al.
Journal Emerg Infect Dis
Impact factor
6.81
Citation count: 2
Date of Entry 2021 Sep 28